Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS-mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.
|Original language||English (US)|
|State||Published - Dec 1 2021|
- Colorectal cancer
- KRAS mutation
- Targeted therapy
ASJC Scopus subject areas
- Cancer Research